Extracellular vesicles-based drug delivery systems for cancer immunotherapy

Tuying Yong; Xin Li; Zhaohan Wei; Lu Gan; Xiangliang Yang

doi:10.1016/j.jconrel.2020.09.028

Extracellular vesicles-based drug delivery systems for cancer immunotherapy

J Control Release. 2020 Dec 10:328:562-574. doi: 10.1016/j.jconrel.2020.09.028. Epub 2020 Sep 16.

Authors

Tuying Yong¹, Xin Li¹, Zhaohan Wei¹, Lu Gan², Xiangliang Yang³

Affiliations

¹ National Engineering Research Center for Nanomedicine, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, PR China.
² National Engineering Research Center for Nanomedicine, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, PR China. Electronic address: Lugan@hust.edu.cn.
³ National Engineering Research Center for Nanomedicine, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, PR China. Electronic address: Yangxl@hust.edu.cn.

PMID: 32946875
DOI: 10.1016/j.jconrel.2020.09.028

Abstract

Extracellular vesicles (EVs), a heterogeneous population of membrane vesicles, are secreted by almost all living cells and contain different proteins, lipids and nucleic acid depending on their sources. Recently, numerous reports indicated EVs could interact with diverse cells in tumor microenvironment and influence both physiological and pathological conditions. Given that EVs regulate tumor immune microenvironment, EVs-based strategies are explored for anti-tumor immunotherapy. In this review, about nine kinds of EVs derived from diverse cells are indicated. The biological functions in tumor immunity, strategies for anti-tumor immunotherapy and further clinical trials of these EVs will be introduced in detail.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Drug Delivery Systems
Extracellular Vesicles*
Humans
Immunotherapy
Neoplasms* / therapy
Tumor Microenvironment